Arca Biopharma Inc., of Westminster, Colo., said the 175th patient has been randomized into GENETIC-AF, a seamless design phase IIb/III trial evaluating the beta blocker and mild vasodilator Gencaro (bucindolol hydrochloride) as a potential treatment for atrial fibrillation.